Liu Yi - Kura Oncology Insider

KURA -- USA Stock  

USD 20.10  0.30  1.47%

  Founder
Dr. Yi Liu, Ph.D. is Chief Scientific Officer of Kura Oncology, Inc. Since March 2015. Dr. Liu cofounded Prior Kura in August 2014 and served as the Chief Scientific Officer of Prior Kura from October 2014 until the Upstream Merger in March 2015. Prior to that, Dr. Liu cofounded and served as Chief Scientific Officer of Wellspring Biosciences LLC, a private biopharmaceutical company, from July 2012 to September 2014. Dr. Liu also cofounded Intellikine, Inc., a private biopharmaceutical company, where he served as Vice President of Drug Discovery from 2007 to May 2012, until its acquisition by Takeda Pharmaceutical Company Limited. Prior to Intellikine, Dr. Liu was the head of the drug design group at the Genomics Institute of the Novartis Research Foundation. Earlier in his career, he held senior scientist positions at both SGX Pharmaceuticals, Inc., a public biopharmaceutical company which was acquired by Eli Lilly and Company in 2008, and Curagen Corporationrationration, a public biopharmaceutical development company
Age: 46  Founder Since 2015      
858-500-8800  http://www.kuraoncology.com
Liu received his Ph.D. in Biochemistry from Princeton University, his MSc in computational chemistry from Beijing University and his BE in Chemical Engineering from Tsinghua University.

Management Efficiency

The company has return on total asset (ROA) of (26.68) % which means that it has lost $26.68 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (48.57) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 7.16 M in liabilities with Debt to Equity (D/E) ratio of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kura Oncology has Current Ratio of 12.12 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. The company was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 32 people.Kura Oncology (KURA) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 32 people. Kura Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.

Kura Oncology Leadership Team

Troy Wilson, Chairman of the Board and Presidentident, CEO, Co-Founder
Steven Stein, Director
John Farnam, COO
Faheem Hasnain, Independent Director
Annette North, Senior Vice President General Counsel
Liu Yi, Co-Founder, Chief Scientific Officer
Thomas Malley, Director
Pingda Ren, Sr. VP of Chemistry and Pharmaceutical Sciences
Antonio Gualberto, Chief Medical Officer
Heidi Henson, CFO, Secretary
Robert Hoffman, Independent Director

Stock Performance Indicators

Did you try this?

Run Fundamentals Comparison Now
   

Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
All  Next Launch Fundamentals Comparison

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">